• QuidelOrtho Corporation recently reported past second-quarter 2026 results, with sales rising to US$630.9 million while net loss narrowed to US$92.9 million, and also reduced its full-year 2026 revenue outlook to a range of US$2.52 billion to US$2.60 billion.
• While losses have eased year over year, the combination of softer first-half sales and lower full-year guidance highlights ongoing pressure from waning COVID testing demand, product exits, and pricing challenges in key markets.
• Next, we’ll examine how the reduced 2026 revenue guidance and ongoing COVID testing headwinds affect QuidelOrtho’s existing investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

QuidelOrtho Investment Narrative Recap

To stay invested in QuidelOrtho today, you need to believe that its broad diagnostics portfolio and international expansion can eventually offset shrinking COVID testing and ongoing product exits. The lowered 2026 revenue outlook reinforces that the key near term catalyst remains execution on non COVID growth, while the biggest risk is that weaker pricing and volume trends, particularly in pressured markets, keep losses from narrowing meaningfully despite some recent improvement.

The most relevant recent announcement is the cut to full year 2026 revenue guidance to US$2.52 billion to US$2.60 billion, down from US$2.70 billion to US$2.75 billion. This reset aligns with analysts’ sharper fair value revisions and highlights how softer first half sales, pricing pressure and portfolio rationalization are feeding directly into expectations for slower expansion in QuidelOrtho’s core diagnostics businesses, at least over the next few quarters.

Yet investors should also be aware that pressure from declining COVID testing and regulatory headwinds in markets like China could...

QuidelOrtho's narrative projects $2.7 billion revenue and $332.2 million earnings by 2029. This implies essentially flat yearly revenue and an earnings increase of about $1.3 billion from -$1.0 billion today.

Uncover how QuidelOrtho's forecasts yield a $12.00 fair value, a 20% downside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were already more cautious, assuming about US$3.0 billion in revenue and unprofitable operations, and see risks like high debt and slower adoption as reasons their narrative could shift further after this guidance cut.

Explore 2 other fair value estimates on QuidelOrtho - why the stock might be worth over 4x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your QuidelOrtho research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free QuidelOrtho research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate QuidelOrtho's overall financial health at a glance.

Ready For A Different Approach?

Our top stock finds are flying under the radar-for now. Get in early:

• The latest GPUs need a type of rare earth metal called Neodymium and there are only 28 companies in the world exploring or producing it. Find the list for free.
• We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 44 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.